
Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown
Published: June 26, 2024
Language: Английский
Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown
Published: June 26, 2024
Language: Английский
Frontiers in Pharmacology, Journal Year: 2023, Volume and Issue: 14
Published: Sept. 6, 2023
Twelve novel neo-tanshinlactone-chalcone hybrid molecules were constructed through a versatile methodology involving the Horner-Wadsworth-Emmons (HWE) olefination of 4-formyl-2H-benzo [h]chromen-2-ones and phosphonic acid diethyl esters, as key step, evaluated for anticancer activity against series four breast cancers their related cell lines, viz. MCF-7 (ER + ve), MDA-MB-231 (ER-ve), HeLa (cervical cancer), Ishikawa (endometrial cancer). The title compounds showed excellent to moderate in vitro anti-cancer range 6.8-19.2 µM (IC50). Compounds 30 (IC50 = 6.8 MCF-7; IC50 8.5 MDA-MB-231) 31 14.4 15.7 exhibited best with compound showing more potent than standard drug tamoxifen. Compound demonstrated strong binding affinity tumor necrosis factor α (TNF-α) molecular docking studies. This is significant because TNFα linked cancer it enhances luminal proliferation by upregulating aromatase. Additionally, virtual ADMET studies confirmed that met Lipinski's rule; displayed high bioavailability, oral absorption, favorable albumin interactions, penetration capabilities; improved blood-brain barrier crossing. Based on aforementioned results, has been identified potential anti-breast lead molecule.
Language: Английский
Citations
15Chemistry & Biodiversity, Journal Year: 2024, Volume and Issue: 21(8)
Published: June 3, 2024
Breast cancer remains a major global health issue, particularly affecting women and contributing significantly to mortality rates. Current treatments for estrogen receptor-positive breast cancers, such as aromatase inhibitors, are effective but often come with side effects resistance issues. This study addresses these gaps by targeting aromatase, an enzyme crucial synthesis, which plays pivotal role in progression. The innovative approach involves synthesizing novel bis-triazolopyridopyrimidines, designed leverage the combined pharmacological benefits of pyridopyrimidine 1,2,4-triazole structures, known their potent inhibition anti-cancer properties. These compounds were synthesized characterized using
Language: Английский
Citations
5Journal of Molecular Structure, Journal Year: 2025, Volume and Issue: unknown, P. 142351 - 142351
Published: April 1, 2025
Language: Английский
Citations
0ChemistrySelect, Journal Year: 2024, Volume and Issue: 9(2)
Published: Jan. 9, 2024
Abstract We have developed a Visible Light Promoted Catalyst‐Free (VLCF) approach to synthesize novel conjugates of Isoniazid and Maleimide. This method involves the formation an electron donor‐acceptor (EDA) complex between isoniazid maleimide photochemical activity this drives transformation. successfully synthesized Isoniazid‐Maleimide derivatives (3a–d) at gram scale under visible light irradiation without additional photo catalyst chromatographic purification resulting in excellent yields recyclable green solvent. Molecular docking was employed predict silico anti‐tubercular binding modes active site enoyl‐ACP reductase, InhA. The newly compounds exhibited high affinity compared Isoniazid‐NAD adduct, indicating their potential for more effective activity. ADME analysis revealed favourable physicochemical properties, lipophilicity, water solubility, pharmacokinetics, drug‐likeness compound 3a, positioning it as promising candidate further drug discovery development.
Language: Английский
Citations
3ChemistrySelect, Journal Year: 2024, Volume and Issue: 9(32)
Published: Aug. 23, 2024
Abstract We developed and evaluated several new fused imidazo[1,2‐d][1,2,4]thiadiazolo[1,2,3]triazoles to see how they perform against bacteria biofilms. Some compounds showed acceptable activity compared the primary standard, Dicloxacillin. of demonstrated significant antibacterial S. aureus , with MIC values ranging from 1.56–12.5 μg/mL. also found anti‐biofilm properties in potent compounds. The results that derivatives 3‐(4‐fluorophenyl)imidazo[1,2‐d] [1,2,3] triazolo[1,5‐b][1,2,4]thiadiazole 8,8‐dioxide 3‐(3,5‐difluorophenyl)imidazo[1,2‐d][1,2,3]triazolo[1,5‐b][1,2,4] thiadiazole were strong agents effective MSSA MRSA biofilm growth inhibitors. conducted silico studies assess molecular interactions more TLR4 proteins (PDB: 3FXI, 3VQ1, 3RG1). Our findings revealed 3‐(4‐chloro‐3,5‐dimethoxyphenyl)imidazo[1,2‐d][1,2,3]triazolo[1,5‐b] [1,2,4]thiadiazole 8,8‐dioxide, 3‐(3,5‐dichlorophenyl)imidazo[1,2‐d] [1,2,3]triazolo[1,5‐b][1,2,4] 3‐(4‐(trifluoromethyl)phenyl)imidazo[1,2‐d][1,2,3]triazolo[1,5‐b][1,2,4] exhibited binding than dicloxacillin. ADME examined this study could potentially inhibit cytochrome P450 CYP2C19 isoform.
Language: Английский
Citations
1Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown
Published: June 26, 2024
Language: Английский
Citations
0